FALLON LYNNETTE C 4

What Happened
Lynnette Fallon, a director of ClearPoint Neuro (CLPT), had 12,417 restricted stock units (RSUs) settle into common shares on May 19, 2026. Following the vesting, 5,091 of those shares were sold on May 20, 2026 in an open-market transaction at a weighted average price of $11.14 per share, producing proceeds of $56,714. The RSU settlement is reported as an exercise/conversion-type event (conversion of the derivative right to shares).

Key Details

• Transaction dates: RSU settlement on 2026-05-19; open-market sale on 2026-05-20. Filing date: 2026-05-21 (timely).
• Sale price and proceeds: weighted average $11.14; range $11.04–$11.20; total proceeds $56,714.
• Shares involved: 12,417 RSUs vested into shares; 5,091 shares sold to the market.
• Purpose/footnotes: RSUs were granted May 22, 2025 and vested per schedule (F1). The sale was made under a Rule 10b5-1 trading plan to cover tax liability from the vesting (F2). F3 notes the price range and that the filer can provide per-price share counts on request.
• Shares owned after transaction: not specified in the provided filing.

Context
This was a scheduled RSU settlement with a partial, planned sale to cover taxes — a routine event for equity compensation and not necessarily a signal of personal views on the company. No outright purchases were reported. Purchases tend to be more informative about insider conviction; this filing documents a taxable-event-driven sale.